Silke Guenther

571 total citations
26 papers, 425 citations indexed

About

Silke Guenther is a scholar working on Oncology, Surgery and Epidemiology. According to data from OpenAlex, Silke Guenther has authored 26 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Surgery and 11 papers in Epidemiology. Recurrent topics in Silke Guenther's work include Bladder and Urothelial Cancer Treatments (15 papers), Multiple and Secondary Primary Cancers (11 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Silke Guenther is often cited by papers focused on Bladder and Urothelial Cancer Treatments (15 papers), Multiple and Secondary Primary Cancers (11 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Silke Guenther collaborates with scholars based in Germany, United States and United Kingdom. Silke Guenther's co-authors include Michaela Kress, Peter W. Reeh, Markus Moehler, Narikazu Boku, Jaffer A. Ajani, Eduardo Yañez Ruiz, Julien Taı̈eb, Min‐Hee Ryu, Yung‐Jue Bang and Vikram K. Chand and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neurophysiology and Annals of Oncology.

In The Last Decade

Silke Guenther

22 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Silke Guenther Germany	9	212	123	110	98	88	26	425
Sumedha Pareek United States	9	120 0.6×	40 0.3×	39 0.4×	83 0.8×	62 0.7×	10	339
Masami Kishi Japan	12	46 0.2×	183 1.5×	81 0.7×	142 1.4×	115 1.3×	21	528
Joy Yang Ge United States	11	362 1.7×	175 1.4×	40 0.4×	41 0.4×	76 0.9×	34	604
Shelby Gorman United States	8	70 0.3×	31 0.3×	60 0.5×	274 2.8×	95 1.1×	11	442
Arif Şanlı Türkiye	9	54 0.3×	56 0.5×	96 0.9×	52 0.5×	53 0.6×	32	350
Ryuusuke Aihara Japan	16	127 0.6×	292 2.4×	223 2.0×	91 0.9×	59 0.7×	33	579
Triantafyllos Paparountas Greece	6	19 0.1×	170 1.4×	30 0.3×	222 2.3×	65 0.7×	6	445
Jean‐Luc Carré France	11	39 0.2×	26 0.2×	20 0.2×	82 0.8×	37 0.4×	24	349
Daishi Chen China	11	27 0.1×	93 0.8×	31 0.3×	329 3.4×	74 0.8×	23	531
Yong Fu China	11	111 0.5×	36 0.3×	35 0.3×	131 1.3×	50 0.6×	40	372

Countries citing papers authored by Silke Guenther

Since Specialization

Citations

This map shows the geographic impact of Silke Guenther's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silke Guenther with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silke Guenther more than expected).

Fields of papers citing papers by Silke Guenther

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silke Guenther. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silke Guenther. The network helps show where Silke Guenther may publish in the future.

Co-authorship network of co-authors of Silke Guenther

This figure shows the co-authorship network connecting the top 25 collaborators of Silke Guenther. A scholar is included among the top collaborators of Silke Guenther based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silke Guenther. Silke Guenther is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gupta, Shilpa, Thomas Powles, Mairead Kearney, et al.. (2025). Criteria Used to Determine Platinum Eligibility in Patients with Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries. European Urology Open Science. 81. 28–36.

Schlack, Katrin, S. Machtens, Thomas Kubin, et al.. (2025). Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study. Journal of Cancer Research and Clinical Oncology. 151(3). 100–100.

Niegisch, Günter, Marc‐Oliver Grimm, Silke Guenther, et al.. (2024). Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Future Oncology. 20(19). 1351–1366. 2 indexed citations

Guenther, Silke, et al.. (2024). Split-Dose Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Literature Review and Network Meta-Analysis. Clinical Genitourinary Cancer. 22(6). 102176–102176. 1 indexed citations

Kearney, Mairead, et al.. (2024). Clinical outcomes with split-dose cisplatin-based regimens in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a systematic literature review (SLR) and network meta-analysis (NMA).. Journal of Clinical Oncology. 42(4_suppl). 589–589.

Gupta, Shilpa, Thomas Powles, Mairead Kearney, et al.. (2024). Age and other criteria influencing nontreatment of patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a physician survey in five European countries (Eu5).. Journal of Clinical Oncology. 42(16_suppl). 4570–4570. 1 indexed citations

Niegisch, Günter, Mairead Kearney, C Weinhold, et al.. (2023). 2386P Factors associated with not receiving systemic treatment (tx) in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany. Annals of Oncology. 34. S1215–S1215. 1 indexed citations

Grivas, Petros, Enrique Grande, Ian D. Davis, et al.. (2023). Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice. ESMO Open. 8(6). 102050–102050. 12 indexed citations

Gupta, Shilpa, Miguel Á. Climent Durán, Srikala S. Sridhar, et al.. (2023). 2371P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts). Annals of Oncology. 34. S1207–S1207. 4 indexed citations

10.

Schlack, Katrin, Thomas Kubin, Markus Ruhnke, et al.. (2023). 2388P Split-dose cisplatin plus gemcitabine use and associated clinical outcomes in the first-line (1L) treatment of locally advanced or metastatic urothelial cancer (la/mUC): Results of a retrospective observational study in Germany (CONVINCE). Annals of Oncology. 34. S1216–S1216. 5 indexed citations

11.

Vaishampayan, Ulka N., Patrick Schöffski, Alain Ravaud, et al.. (2019). Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. Journal for ImmunoTherapy of Cancer. 7(1). 275–275. 49 indexed citations

12.

Grivas, Petros, Bradley J. Monk, Daniel P. Petrylak, et al.. (2019). Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. Targeted Oncology. 14(5). 505–525. 36 indexed citations

13.

Taı̈eb, Julien, Markus Moehler, Narikazu Boku, et al.. (2018). Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treatment Reviews. 66. 104–113. 72 indexed citations

14.

Vaishampayan, Ulka N., Patrick Schöffski, Alain Ravaud, et al.. (2018). First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial. Annals of Oncology. 29. viii310–viii311. 1 indexed citations

15.

Bharmal, Murtuza, Silke Guenther, & Mairead Kearney. (2017). Epidemiology of Locally Advanced or Metastatic Urothelial Cancer In The US, Europe And Japan. Value in Health. 20(9). A419–A419. 8 indexed citations

16.

Bharmal, Murtuza, et al.. (2017). Second-Line Therapy In Patients with Locally Advanced or Metastatic Urothelial Cancer: A Systematic Literature Review. Value in Health. 20(9). A414–A414. 1 indexed citations

17.

Yamaguchi, Kensei, Masahiko Ando, Akira Ooki, et al.. (2016). Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy. Clinical Colorectal Cancer. 16(2). e29–e37. 18 indexed citations

18.

Cutsem, Eric Van, Claus‐Henning Köhne, Gunnar Folprecht, et al.. (2016). Efficacy and safety of first-line cetuximab + FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.. Journal of Clinical Oncology. 34(4_suppl). 647–647. 4 indexed citations

19.

Yamaguchi, Kazuya, Masashi Ando, Akira Ooki, et al.. (2015). 2120 Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI + cetuximab in the CRYSTAL study. European Journal of Cancer. 51. S370–S371. 3 indexed citations

20.

Guenther, Silke, Peter W. Reeh, & Michaela Kress. (1999). Rises in [Ca²⁺]_i mediate capsaicin‐ and proton‐induced heat sensitization of rat primary nociceptive neurons. European Journal of Neuroscience. 11(9). 3143–3150. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact